智通财经APP讯，一脉阳光(02522)发布公告，于2025年11月18日斥资6.02万港元回购3500股股份。 ...

一脉阳光(02522)发布公告，于2025年11月18日斥资6.02万港元回购3500股股份。 ...

格隆汇11月18日丨一脉阳光(02522.HK)公告，11月18日耗资6万港元回购3500股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江西一脈陽光集團股份有限公司 呈交日期： 2025年11月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02522 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

Core Viewpoint - The company is positioned as a leader in China's third-party medical imaging industry, with significant growth potential driven by AI and data asset management, leading to a "buy" rating with a target price of 30.4 HKD for 2026 [1][2]. Financial Projections - Expected revenue for the company from 2025 to 2027 is projected at 1.05 billion, 1.39 billion, and 1.68 billion RMB, reflecting year-on-year growth rates of 38.1%, 32.2%, and 21.2% respectively [1]. - Net profit is forecasted to be 25 million, 60 million, and 105 million RMB for the same years, with significant growth rates of 137.7% and 76.5% in 2026 and 2027 [1]. - EBITDA is anticipated to reach 236 million, 282 million, and 341 million RMB, with year-on-year growth of 43.0%, 19.5%, and 20.9% [1]. Business Model and Operations - The company operates a leading third-party medical imaging service platform in China, with a focus on imaging center services, imaging solutions, and the "Yimai Cloud" platform, achieving a revenue of 467 million RMB in the first half of 2025, a 12.9% increase year-on-year [2]. - Imaging solutions revenue reached 161 million RMB, showing an impressive growth of 88.9%, and accounting for 34.5% of total revenue [2]. - The company has established a nationwide network of imaging centers, with 115 centers operational across 17 provinces, creating multiple barriers to entry through equipment, licenses, and brand resources [3]. Data Asset Management and AI Integration - The company has built a high-quality medical imaging database covering over 200 diseases, with daily additions of 20,000 to 30,000 structured data entries, facilitating the exploration of data asset management and commercialization [4]. - The company has launched a full-modal AI-assisted diagnostic product, achieving leading results in image understanding and report generation, and has developed a closed-loop ecosystem for data-driven model iteration and service feedback [4].

Core Viewpoint - The report from Tianfeng Securities projects significant revenue and profit growth for Yimai Sunshine from 2025 to 2027, highlighting its leadership in China's third-party medical imaging industry and potential as a medical data asset operator [1] Group 1: Financial Projections - Expected revenues for Yimai Sunshine are projected at 1.05 billion, 1.39 billion, and 1.68 billion yuan for 2025, 2026, and 2027, representing year-on-year growth of 38.1%, 32.2%, and 21.2% respectively [1] - Net profits are forecasted to be 25 million, 60 million, and 105 million yuan for the same years, with 2026 and 2027 showing year-on-year growth rates of 137.7% and 76.5% [1] - EBITDA is anticipated to reach 236 million, 282 million, and 341 million yuan, with year-on-year increases of 43.0%, 19.5%, and 20.9% [1] Group 2: Business Model and Market Position - Yimai Sunshine is recognized as a leading third-party medical imaging service platform in China, with a focus on imaging center services, imaging solutions, and the Yimai Cloud, which are synergistically integrated [1] - The company achieved a revenue of 467 million yuan in the first half of 2025, marking a year-on-year increase of 12.9%, with imaging solutions revenue growing by 88.9% to 161 million yuan, accounting for 34.5% of total revenue [1] - The company has established a nationwide network of imaging centers, operating 115 centers across 17 provinces as of June 30, 2025, creating multiple barriers to entry through equipment, licenses, and resources [2] Group 3: Data Assetization and AI Integration - Yimai Sunshine has accumulated a high-quality medical imaging database covering over 200 diseases and more than 10 million cases, generating 20,000 to 30,000 new structured data entries daily [3] - The company has completed the full process exploration of "data resources - data assets - data trading," with several imaging data products listed and traded on data exchanges [3] - The company has launched the MIIA model and AI-assisted diagnostic products, achieving leading results in image understanding and report generation, establishing a closed-loop ecosystem driven by data [3]

Group 1 - The core point of the news is that southbound funds have reduced their holdings in Yipai Sunshine (02522.HK) by 436,000 shares on November 17, 2025, marking a cumulative net reduction of 1,467,500 shares over the last five trading days [1] - Over the past 20 trading days, there have been 11 days of net reductions in holdings by southbound funds, totaling 1,294,000 shares [1] - As of now, southbound funds hold 125 million shares of Yipai Sunshine, which accounts for 42.66% of the company's total issued ordinary shares [1] Group 2 - On November 17, 2025, the total number of shares held was 125 million, with a decrease of 436,000 shares, reflecting a change of -0.35% [2] - The trading history shows fluctuations in holdings, including an increase of 184,500 shares on November 14, 2025, and a decrease of 949,000 shares on November 12, 2025 [2] - Yipai Sunshine Group Co., Ltd. primarily engages in specialized medical imaging services, providing imaging examination and diagnostic services through flagship imaging centers, and offering solutions for hospitals to select and procure imaging equipment [2]

一脉阳光(02522)公布，2025年11月17日耗资约99.48万港元回购5.9万股股份。 ...

智通财经APP讯，一脉阳光(02522)公布，2025年11月17日耗资约99.48万港元回购5.9万股股份。 ...

格隆汇11月17日丨一脉阳光(02522.HK)公告，11月17日耗资99.4万港元回购5.9万股。 ...